Uscom Ltd. engages in the development, design, manufacture, and marketing of non-invasive cardiovascular and pulmonary medical devices. The company is headquartered in Sydney, New South Wales. The firm has three practice suites of devices in the field of cardiac, vascular and pulmonary monitoring, such as the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. USCOM 1A is a non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities, and is used to guide treatment. Uscom BP+ is a supra-systolic oscillometric central blood pressure monitor, which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterization. Uscom SpiroSonic digital ultrasonic spirometers are high fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology.
Uscom (ASX: UCM)
- Home
- Uscom (ASX: UCM)
Here are the latest articles on Uscom (ASX: UCM)
Uscom hits jackpot with China approval for hypertension monitor
April 19, 2021
More than 230 million adults in China suffering from hypertension, a modifiable risk factor, will be able to reduce their risk of heart attack now that medtech company Uscom (ASX: UCM) has had the BP+ device approved for sale by Chinese regulators. Installed on the International Space Station, the BP+ is a patent-protected device that
Uscom releases ventilator calibrator as demand surges through COVID-19
August 5, 2020
To assist with maintenance of ventilator devices being used to combat the coronavirus pandemic, Uscom (ASX: UCM) has released the SpiroSonic VENTITEST ventilator testing device which will allow medical professionals to calibrate ventilators, making it the first digital ultrasonic calibrator of its kind. With the need for ventilators having risen dramatically as the world grapples
Recent Articles
